Get the Stockscreener App
2.62
1.87%
-0.05
After Hours:
2.65
0.03
+1.15%
Immunitybio Inc Stock (IBRX) Forecast
The Immunitybio Inc (IBRX) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $14.54, representing a +455.06% increase from the current price of $2.62. The highest analyst price target is $14.63, and the lowest is $14.45.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month IBRX Price Target
Average 14.75
(+462.98% Upside)
Is Immunitybio Inc (IBRX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 28.04 | Buy |
| STOCH(9,6) | 3.0161 | Buy |
| STOCHRSI(14) | 0.9132 | Buy |
| MACD(12,26) | -0.5834 | Sell |
| ADX(14) | 30.68 | Sell |
| William %R | -99.60 | Buy |
| CCI(14) | -81.01 | Neutral |
Buy: 4
Sell: 2
Neutral: 1
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
3.233
Sell
|
3.1927
Sell
|
| MA20 |
4.0765
Sell
|
3.7384
Sell
|
| MA50 |
4.4606
Sell
|
4.1967
Sell
|
| MA100 |
4.1432
Sell
|
4.4328
Sell
|
| MA200 |
5.216
Sell
|
4.4051
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, IBRX could be considered a Strong Sell, with 17 technical analysis indicators signaling 4 Buy signals, 12 signaling Sell signals and 1 Neutral signals. This might not be a good time to consider opening new positions on IBRX, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 28.04 indicates that IBRX is oversold. This indicates that IBRX price has experienced a significant decline over a specified lookback period, potentially leading to a rebound.
- STOCH (Stochastic Oscillator): The STOCH value of 3.0161 indicates that IBRX is oversold. This indicates that IBRX price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 0.9132 indicates that IBRX is oversold. This suggests that IBRX price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 30.68 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -81.01 indicates that IBRX is still oversold but not to an extreme extent.
Long-term IBRX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Immunitybio Inc financial reports and earnings history, Immunitybio Inc (IBRX) stock could reach $25.62 by 2030, $93.01 by 2040 and $178.73 by 2050. See the projected annual prices until 2050 of the Immunitybio Inc stock below:
- Immunitybio Inc (IBRX) is expected to reach an average price of $13.72 in 2035, with a high prediction of $15.23 and a low estimate of $12.22. This indicates an $423.81% rise from the last recorded price of $2.62.
- Immunitybio Inc (IBRX) stock is projected to chart a bullish course in 2040, with an average price target of $91.83, representing an $3,405% surge from its current level. The forecast ranges from a conservative $92.26 to a sky-high $93.01.
- Our analysts predict Immunitybio Inc (IBRX) to jump 2,357% by 2045, soaring from $64.39 to an average price of $64.37, potentially reaching $65.83. While $64.39 is the low estimate, the potential upside is significant.
- Immunitybio Inc (IBRX) stock is expected to climb by 2050, reaching an average of $178.16, a $6,700% jump from its current level. However, a wide range of estimates exists, with high and low targets of $178.73 and $178.22, respectively, highlighting the market's uncertainty.
Immunitybio Inc Stock (IBRX) Year by Year Forecast
Immunitybio Inc Stock (IBRX) Price Forecast for 2025
Immunitybio Inc Stock (IBRX) is expected to reach an average price of $14.75 in 2025, with a high prediction of $15.87 and a low estimate of $13.63. This indicates an +462.98% rise from the last recorded price of $2.62.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $15.10 | $14.45 | $14.63 | +476.48% |
| February, 2025 | $16.55 | $16.30 | $15.50 | +531.49% |
| March, 2025 | $15.87 | $15.90 | $15.87 | +505.59% |
| April, 2025 | $15.58 | $15.83 | $15.66 | +494.59% |
| May, 2025 | $14.08 | $15.02 | $15.18 | +437.40% |
| June, 2025 | $14.60 | $14.29 | $14.19 | +457.30% |
| July, 2025 | $14.92 | $14.68 | $14.64 | +469.58% |
| August, 2025 | $16.04 | $15.70 | $15.82 | +512.38% |
| September, 2025 | $15.45 | $15.60 | $15.31 | +489.54% |
| October, 2025 | $14.56 | $14.73 | $15.53 | +455.64% |
| November, 2025 | $14.22 | $14.19 | $13.70 | +442.72% |
| December, 2025 | $13.56 | $13.63 | $13.46 | +417.59% |
Immunitybio Inc Stock (IBRX) Price Forecast for 2026
The predicted value for Immunitybio Inc (IBRX) in 2026 is set at an average of $11.05. Estimates vary from a peak of $12.95 to a trough of $9.1482, indicating an +321.65% surge from the present price of $2.62.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $12.29 | $12.44 | $12.95 | +369.18% |
| February, 2026 | $11.37 | $11.89 | $11.48 | +334.12% |
| March, 2026 | $10.41 | $10.98 | $10.68 | +297.15% |
| April, 2026 | $9.5471 | $10.09 | $10.42 | +264.39% |
| May, 2026 | $10.93 | $10.06 | $10.01 | +317.12% |
| June, 2026 | $11.02 | $10.70 | $10.80 | +320.61% |
| July, 2026 | $11.83 | $10.85 | $11.55 | +351.59% |
| August, 2026 | $12.19 | $12.43 | $12.35 | +365.39% |
| September, 2026 | $10.49 | $11.05 | $11.73 | +300.19% |
| October, 2026 | $10.31 | $10.40 | $9.6964 | +293.38% |
| November, 2026 | $9.6679 | $9.7679 | $9.9868 | +269.00% |
| December, 2026 | $9.0497 | $9.1482 | $9.3882 | +245.41% |
Immunitybio Inc Stock (IBRX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Immunitybio Inc (IBRX) is $15.11, with a high forecast of $29.37 and a low forecast of $0.853. This indicates an +476.82% increase from the last price of $2.62.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $9.5911 | $9.4604 | $9.4211 | +266.07% |
| February, 2027 | $9.4526 | $9.4726 | $9.3626 | +260.78% |
| March, 2027 | $9.0144 | $9.0836 | $9.2829 | +244.06% |
| April, 2027 | $6.8558 | $7.4358 | $8.8297 | +161.67% |
| May, 2027 | $5.4372 | $5.8422 | $5.9565 | +107.53% |
| June, 2027 | $4.569 | $4.949 | $5.538 | +74.39% |
| July, 2027 | $4.9705 | $4.4398 | $4.7205 | +89.71% |
| August, 2027 | $3.5519 | $4.3719 | $4.6112 | +35.57% |
| September, 2027 | $2.0937 | $3.0034 | $3.1023 | -20.09% |
| October, 2027 | $1.4352 | $2.2552 | $1.9341 | -45.22% |
| November, 2027 | $1.2834 | $1.1934 | $3.8234 | -51.02% |
| December, 2027 | $30.92 | $0.853 | $29.37 | +1,080% |
Immunitybio Inc Stock (IBRX) Price Forecast for 2028
In 2028, Immunitybio Inc (IBRX) is projected to reach an average price of $36.32, with a high projection of $38.14 and a low estimate of $34.51. This indicates an +1,286% rise from the last price of $2.62.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $34.70 | $34.89 | $34.28 | +1,224% |
| February, 2028 | $34.02 | $36.03 | $34.29 | +1,198% |
| March, 2028 | $36.19 | $34.51 | $36.03 | +1,281% |
| April, 2028 | $38.78 | $36.67 | $37.76 | +1,380% |
| May, 2028 | $37.18 | $38.32 | $37.66 | +1,319% |
| June, 2028 | $37.44 | $37.18 | $37.34 | +1,329% |
| July, 2028 | $37.92 | $37.56 | $36.83 | +1,347% |
| August, 2028 | $37.93 | $37.71 | $37.68 | +1,348% |
| September, 2028 | $38.93 | $38.80 | $38.11 | +1,386% |
| October, 2028 | $37.81 | $37.84 | $38.14 | +1,343% |
| November, 2028 | $36.98 | $37.56 | $37.17 | +1,311% |
| December, 2028 | $35.04 | $35.98 | $36.47 | +1,237% |
Immunitybio Inc Stock (IBRX) Price Forecast for 2029
The 2029 price forecast for Immunitybio Inc Stock (IBRX) is $30.50 on average, with a high prediction of $35.35 and a low estimate of $25.64. This represents an +1,064% increase from the previous price of $2.62.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $35.08 | $35.14 | $34.71 | +1,239% |
| February, 2029 | $34.90 | $34.87 | $34.62 | +1,232% |
| March, 2029 | $35.58 | $35.57 | $35.35 | +1,258% |
| April, 2029 | $34.54 | $34.81 | $34.74 | +1,218% |
| May, 2029 | $33.11 | $33.28 | $34.40 | +1,164% |
| June, 2029 | $32.33 | $32.37 | $32.01 | +1,134% |
| July, 2029 | $31.25 | $31.52 | $31.46 | +1,093% |
| August, 2029 | $29.41 | $29.56 | $30.99 | +1,023% |
| September, 2029 | $28.06 | $28.59 | $28.50 | +970.90% |
| October, 2029 | $27.00 | $27.03 | $27.15 | +930.58% |
| November, 2029 | $25.24 | $25.78 | $26.45 | +863.52% |
| December, 2029 | $26.19 | $25.64 | $25.27 | +899.51% |
Immunitybio Inc Stock (IBRX) Price Forecast for 2030
Immunitybio Inc Stock (IBRX) is expected to reach an average price of $20.85 in 2030, with a high forecast of $26.30 and a low forecast of $15.40. This signifies an +695.71% surge from the last price of $2.62.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $25.09 | $25.70 | $25.62 | +857.66% |
| February, 2030 | $26.10 | $25.45 | $25.82 | +896.32% |
| March, 2030 | $26.03 | $26.35 | $26.30 | +893.37% |
| April, 2030 | $24.11 | $24.88 | $25.43 | +820.20% |
| May, 2030 | $23.15 | $23.36 | $23.68 | +783.70% |
| June, 2030 | $22.08 | $22.18 | $22.72 | +742.59% |
| July, 2030 | $20.91 | $21.01 | $21.69 | +698.07% |
| August, 2030 | $21.01 | $21.10 | $20.96 | +701.99% |
| September, 2030 | $20.44 | $20.46 | $20.58 | +679.97% |
| October, 2030 | $19.45 | $19.56 | $20.16 | +642.32% |
| November, 2030 | $16.85 | $17.43 | $19.15 | +543.19% |
| December, 2030 | $14.99 | $15.40 | $15.73 | +472.31% |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):